LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

Stock Information for Lixte Biotechnology Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lixte Biotechnology Holdings Inc.

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
New Findings Show how LIXTE's Lead Clinical Compound, LB-100, is Metabolized to its Active Form
LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer
LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.